Sanara MedTech (NASDAQ:SMTI) and Bionik Laboratories (OTCMKTS:BNKL) Financial Review

Sanara MedTech (NASDAQ:SMTI) and Bionik Laboratories (OTCMKTS:BNKL) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, analyst recommendations, dividends, risk, earnings, valuation and institutional ownership.

Valuation and Earnings

This table compares Sanara MedTech and Bionik Laboratories’ gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Sanara MedTech $15.59 million 11.89 -$4.36 million ($0.64) -37.95
Bionik Laboratories $1.19 million 3.88 -$13.62 million ($2.25) -0.36

Sanara MedTech has higher revenue and earnings than Bionik Laboratories. Sanara MedTech is trading at a lower price-to-earnings ratio than Bionik Laboratories, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

5.0% of Sanara MedTech shares are held by institutional investors. 59.2% of Sanara MedTech shares are held by company insiders. Comparatively, 40.4% of Bionik Laboratories shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Risk and Volatility

Sanara MedTech has a beta of 2.25, meaning that its stock price is 125% more volatile than the S&P 500. Comparatively, Bionik Laboratories has a beta of -0.47, meaning that its stock price is 147% less volatile than the S&P 500.

Profitability

This table compares Sanara MedTech and Bionik Laboratories’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Sanara MedTech -21.10% -16.89% -14.72%
Bionik Laboratories -759.08% -190.99% -49.03%

Analyst Ratings

This is a breakdown of recent ratings and target prices for Sanara MedTech and Bionik Laboratories, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Sanara MedTech 0 0 1 0 3.00
Bionik Laboratories 0 0 0 0 N/A

Sanara MedTech presently has a consensus target price of $45.00, suggesting a potential upside of 85.26%. Given Sanara MedTech’s higher probable upside, equities research analysts clearly believe Sanara MedTech is more favorable than Bionik Laboratories.

Summary

Sanara MedTech beats Bionik Laboratories on 12 of the 13 factors compared between the two stocks.

Sanara MedTech Company Profile

Sanara MedTech, Inc.engages in the development, marketing, and distribution of biotechnology products to physicians, hospitals, and clinics. It offers CellerateRX Surgical Activated Collagen Adjuvant and HemaQuell Resorbable Bone Hemostat. The company was founded in 1982 and is headquartered in Fort Worth, TX.

Bionik Laboratories Company Profile

Bionik Laboratories Corp. engages in the provision of rehabilitation and mobility solutions to individuals with neurological disorders. Its products include InMotion ARM, InMotion HAND, and InMotion WRIST. The company was founded by Michal Prywata and Thiago Caires on January 8, 2010 and is headquartered in Watertown, MA.

Receive News & Ratings for Sanara MedTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanara MedTech and related companies with MarketBeat.com's FREE daily email newsletter.